

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form S-8

REGENERON PHARMACEUTICALS INC
 Form S-8
 September 24, 2004

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON SEPTEMBER 24, 2004.

REGISTRATION NO. 333-

SECURITIES AND EXCHANGE COMMISSION
 WASHINGTON, D.C. 20549
 FORM S-8
 REGISTRATION STATEMENT
 UNDER
 THE SECURITIES ACT OF 1933

REGENERON PHARMACEUTICALS, INC.
 (Exact Name of Registrant as Specified in Its Charter)

NEW YORK	13-3444607
(State or Other Jurisdiction	(I.R.S. Employer
of Incorporation or Organization)	Identification No.)

777 OLD SAW MILL RIVER ROAD
 TARRYTOWN, NEW YORK 10591-6707
 (914) 347-7000
 (Address, Including Zip Code, and Telephone Number, Including Area Code,
 of Principal Executive Offices)

2000 LONG-TERM INCENTIVE PLAN

(Full Title of the Plans)

STUART KOLINSKI, ESQ.
 VICE PRESIDENT, GENERAL COUNSEL AND SECRETARY
 777 OLD SAW MILL RIVER ROAD
 TARRYTOWN, NEW YORK 10591-6707
 (914) 347-7000
 (Name, Address and Telephone Number of Agent for Service)

Copies to:

DAVID GOLDSCHMIDT, ESQ.
 SKADDEN, ARPS, SLATE, MEAGHER & FLOM LLP
 FOUR TIMES SQUARE
 NEW YORK, NEW YORK 10036-6522
 (212) 735-3000

CALCULATION OF REGISTRATION FEE

TITLE OF SECURITIES TO BE REGISTERED	AMOUNT TO BE REGISTERED (1)	PROPOSED MAXIMUM OFFERING PRICE PER SHARE (2) (3)	PROPOSED MAXIMUM AGGREGATE OFFERING PRICE (3)
Common Stock, par value \$0.001 per share	7,500,000 shares	\$9.075	\$68,062,500

(1) Pursuant to Rule 416 under the Securities Act of 1933, as amended, (the

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form S-8

"Securities Act") this Registration Statement shall also cover, in addition to the number of shares stated above, an indeterminate number of additional shares of Common Stock, par value \$.001 ("Common Stock") of the Registrant which may become issuable under the Registrant's 2000 Long-Term Incentive Plan (the "2000 Plan") by reason of certain corporate transactions or events, including any stock dividend, stock split or any other similar transaction effected which results in an increase in the number of the Registrant's outstanding shares of Common Stock.

- (2) The fee is based solely on the 7,500,000 shares of Common Stock newly available for issuance under the 2000 Plan and is estimated in accordance with paragraphs (c) and (h) of Rule 457 under the Securities Act solely for the purpose of calculating the registration fee based upon the average of the high and low sales prices for a share of Common Stock as reported on the NASDAQ National Market on September 20, 2004.
- (3) Estimated solely for the purpose of calculating the registration fee.

This Registration Statement shall become effective upon filing in accordance with Rule 462(a) under the Securities Act.

Explanatory Note

This registration statement is being filed solely to register the issuance of up to 7,500,000 additional shares of Common Stock of the Registrant pursuant to the Registrant's 2000 Plan.

This registration statement is being filed pursuant to General Instruction E of Form S-8 under the Securities Act ("Instruction E"), and includes the registration statement facing page, this page, the signature page, an exhibit index and relevant opinions and consents. Pursuant to Instruction E, the contents of the Registrant's registration statements on Form S-8 (File Nos. 333-61132 and 333-97375) filed with the Securities and Exchange Commission on May 17, 2001 and July 30, 2002, respectively, are incorporated by reference into this Registration Statement.

SIGNATURES

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THE REGISTRANT CERTIFIES THAT IT HAS REASONABLE GROUNDS TO BELIEVE THAT IT MEETS ALL OF THE REQUIREMENTS FOR FILING ON FORM S-8 AND HAS DULY CAUSED THIS REGISTRATION STATEMENT TO BE SIGNED ON ITS BEHALF BY THE UNDERSIGNED, THEREUNTO DULY AUTHORIZED, IN THE VILLAGE OF TARRYTOWN, STATE OF NEW YORK, ON THE 24TH DAY OF SEPTEMBER, 2004.

REGENERON PHARMACEUTICALS, INC.

By: /s/ Leonard S. Schleifer, M.D., Ph.D.

Leonard S. Schleifer, M.D., Ph.D.
President and Chief Executive Officer

Each person whose signature appears below hereby constitutes and appoints Leonard S. Schleifer and Stuart A. Kolinski, and each of them, his true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him and in his name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) and additions to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorneys-in-fact

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form S-8

and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his substitute or substitutes may lawfully do or cause to be done by virtue hereof.

PURSUANT TO THE REQUIREMENTS OF THE SECURITIES ACT OF 1933, THIS REGISTRATION STATEMENT HAS BEEN SIGNED BY THE FOLLOWING PERSONS IN THE CAPACITIES AND ON THE DATES INDICATED.

NAME -----	TITLE -----	
/s/ P. Roy Vagelos, M.D. ----- P. Roy Vagelos, M.D.	Chairman of the Board of Directors	Septem
/s/ Leonard S. Schleifer, M.D., Ph.D. ----- Leonard S. Schleifer, M.D., Ph.D.	President and Chief Executive Officer and Director (Principal Executive Officer)	Septem
/s/ Murray A. Goldberg ----- Murray A. Goldberg	Senior Vice President, Finance & Administration, Chief Financial Officer, Treasurer and Assistant Secretary (Principal Financial Officer)	Septem
/s/ Douglas S. McCorkle ----- Douglas S. McCorkle	Controller and Assistant Treasurer (Chief Accounting Officer)	Septem
/s/ Charles A. Baker ----- Charles A. Baker	Director	Septem
/s/ Michael S. Brown, M.D. ----- Michael S. Brown, M.D.	Director	Septem
/s/ Alfred G. Gilman, M.D., Ph.D. ----- Alfred G. Gilman, M.D., Ph.D.	Director	Septem
/s/ Joseph L. Goldstein, M.D. ----- Joseph L. Goldstein, M.D.	Director	Septem
/s/ Arthur F. Ryan ----- Arthur F. Ryan	Director	Septem
/s/ Eric M. Shooter, Ph.D. ----- Eric M. Shooter, Ph.D.	Director	Septem

Edgar Filing: REGENERON PHARMACEUTICALS INC - Form S-8

/s/ George Sing

George Sing

Director

Septem

/s/ George D. Yancopoulos, M.D., Ph.D.

George D. Yancopoulos, M.D., Ph.D.

Director

Septem

EXHIBIT INDEX

EXHIBIT
NUMBER

- 4.1 (a, b, c) Restated Certificate of Incorporation, as of June 21, 1991, as amended on October 18, 1996 and December 17, 2001.
- 4.2 (d) By-Laws of the Company, currently in effect (amended as of January 22, 1995).
- 4.3 (e) Specimen common stock certificate.
- 5.1 Opinion of Skadden, Arps, Slate, Meagher & Flom LLP.
- 23.1 Consent of PricewaterhouseCoopers LLP, Independent Accountants.
- 23.2 Consent of Skadden, Arps, Slate, Meagher & Flom LLP (included in Exhibit 5.1).
- 24.1 Power of Attorney (included on signature page).

-
- (a) Incorporated by reference to the Company's Form 10-Q for the quarter ended June 30, 1991, filed with the Commission on August 13, 1991.
- (b) Incorporated by reference to the Company's Form 10-Q for the quarter ended September 30, 1996, filed with the Commission on November 5, 1996.
- (c) Incorporated by reference to the Company's Form 10-K for the year ended December 31, 2001, filed with the Commission on March 22, 2002.
- (d) Incorporated by reference to the Company's Form 10-K for the year ended December 31 1994, filed with the Commission on March 30, 1995.
- (e) Incorporated by reference to Exhibit (a) to the Company's Form 8-A, filed with the Commission on February 20, 1991.